23:17:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Biosergen är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av diverse läkemedel. Produktportföljen inkluderar exempelvis bolagets produkt BSG005, ett svampdödande läkemedel i klinisk fas. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs i Norge. Biosergen grundades år 2004 och har sitt huvudkontor i Solna.

Kalender

2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-06-30 Årsstämma 2022
2022-05-31 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning BIOSGN 0.00 SEK
2022-03-31 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3
2022-03-31 13:17:36

Thursday, March 31, 2022: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the fourth quarter 2021. The interim report is available as an attached document and on the company website (www.biosergen.net)

Biosergen AB was registered in February 2021. On April 16, 2021, the company acquired Biosergen AS with the subsidiary Select Pharma PTY LTD and formed the group with Biosergen AB as parent company. The rules of reverse acquisitions are applied why Biosergen AS is to be seen as the parent company in the group in 2020. Hence 2020 comparative figures relate to Biosergen AS with its subsidiary Select Pharma Pty Ltd.

Summary of the Interim Report for Q4 2021

Amounts in SEK '000 Q4 Jan.-Dec. 2021 Jan.-Dec. 2020
Consolidated group 8 861 11 570 4 432
revenue
Consolidated group -14 950 -34 077 -6 226
loss before
depreciation
Consolidated group - 14 950 -34 077 -6 226
loss before net
financials
Consolidated net -15 034 -34 318 -6 724
result
Consolidated earnings -1,42
per share (EPS)

Highlights during Q4 2021
  • On November 30, 2021, Biosergen AB announced publication of the interim report for the third quarter 2021

Highlights after the period

There have been no highlights after the period.

The Financial report can be found on our website: https://biosergen.net/investors/filings

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net

Certified Adviser

Erik Penser Bank

Telefon: +46 8 463 8000

E-mail: certifiedadvisor@penser.se

This information is such information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on March 31, 2022.